LeadershiP

Jerome V. Dwyer is a distinguished leader at the forefront of healthcare, where medicine, technology, and artificial intelligence (AI) converge. As CEO of QNDX, Dr. Dwyer is pioneering advancements that are transforming the landscape of medical technology, particularly in AI, quantum computing, and cybersecurity.

Dr. Dwyer is dedicated to integrating AI into healthcare, with a special focus on remote monitoring systems that improve diagnostic accuracy and patient outcomes. His collaborations with global companies have expanded the horizons of personalized medicine, making treatments more targeted and effective. At QuantumNext DX, Dr. Dwyer drives initiatives that leverage quantum computing and AI to propel advancements in precision medicine, agricultural innovation, and drug discovery. His leadership fosters strategic partnerships between academia and industry, addressing global challenges such as food insecurity and ensuring sustainable solutions for the future.

Dr. Dwyer’s expertise is underscored by his participation in several pivotal clinical trials, including the Active Capture Control Using Early Detection Study (ACE), Lumos-T-Safely Reduces Routine Office Device Follow-up (TRUST), and the IMPACT study on BIOTRONIK Home Monitoring. His commitment to advancing healthcare is also reflected in his interests in cybersecurity, where he is focused on safeguarding health systems from emerging threats in the digital age.

A successful entrepreneur, investor, and advisor, Dr. Dwyer has a passion for building businesses that utilize AI and advanced technologies. His expertise in intellectual property monetization and corporate patent assessment highlights his innovative approach to business and technology. His leadership extends beyond QuantumNext DX, as he maintains a full-time cardiology practice at Missouri Baptist Medical Center in St. Louis, with additional offices in Union, Missouri, and Washington County Memorial Hospital. 

Dr. Dwyer is also committed to service through his roles as a trustee for the SSM Health Foundation and a member of the St. Louis University Board of Trustees. His career is defined by a relentless pursuit of progress in healthcare, making it more personalized, efficient, and secure. 

As a thought leader and visionary, Dr. Dwyer continues to shape the future of medical technology, ensuring that the innovations he spearheads have a lasting impact on patient care and the broader healthcare industry.

Dan Didier is a pioneer in the field of quantum computing, with a robust background in developing algorithms that deliver cutting-edge solutions across various industries. As the co-founder and Chief Scientific Officer of QNDX, Didier is using the unparalleled computational speed of quantum computers to revolutionize areas such as medical technology, business, finance, geospatial, and agriculture. His research in advanced superconductivity and qubit technology has laid the foundation for new applications that address complex challenges with unprecedented efficiency.

In 2021, Didier initiated the design of a quantum computer capable of executing highly complex simulations and analytical programs to deepen our understanding of intricate systems and phenomena. This groundbreaking endeavor reflects his unwavering commitment to advancing computational technology. Didier’s visionary work has propelled QNDX to the forefront of quantum innovation, accelerating technological progress on a global scale.

With decades of expertise in artificial intelligence (AI) and machine learning, Didier has been instrumental in integrating these technologies across various sectors. In the 1990s, he developed a revolutionary program to analyze digital communications using advanced natural language processing techniques, transforming vast amounts of raw data into actionable insights on trends, public opinion, emerging issues, and even disease states.

During his tenure at Incyte Genomics and Celera,  Didier was involved in the assembly of the human genome. His work in genomics extended into the late 1990s and early 2000s, where his projects focused on understanding the expressed human genome. These efforts were crucial in identifying genetic variations that influence gene expression, leading to significant advancements in precision medicine and personalized healthcare.

Didier is a leader in cybersecurity, with over 40 years of work spanning across various countries and industries. His expertise includes developing cybersecurity solutions that protect critical infrastructure and ensure the security of digital information. Didier has established and directed cybersecurity programs that address emerging threats, leveraging his knowledge in machine learning and AI to develop automated solutions. His work has made significant strides in safeguarding sensitive information and securing digital environments. Didier’s commitment to cybersecurity is further demonstrated through his passion for education, and workforce development where he founded cybersecurity and advanced programming classes at St. John Vianney High School, mentoring the next generation of cybersecurity leaders.

 Didier's contributions to biomedical advancement and drug discovery are extensive and reflect his deep expertise in molecular biology and genomics. In the 1980s, Didier designed a computer program capable of analyzing complex systems with countless interconnected variables. This program was instrumental in modeling phenomena like weather systems, providing valuable insights into the unpredictability of complex systems—a concept crucial for understanding climate change, financial markets, and biological effects. 

At DNA Tree and ScriptAlert, Didier developed DNA analysis programs and identified genes that cause adverse drug reactions, contributing to safer and more effective therapies. His role in genomics has been instrumental in identifying gene mutations and screening compounds for treatment, greatly advancing the fields of precision medicine and healthcare innovation.

In drug discovery, Didier managed a North American sales unit at Promega, generating significant revenue while advancing the development of new therapies. His work at Cogent Neuroscience was pivotal in identifying and characterizing genes involved in nerve regeneration after brain trauma, further advancing the understanding of neurological recovery.

Tina Rene’ Sappington is the Vice President & Director of Purpose and Impact at QNDX, where she plays a crucial role in guiding the company through its rapid expansion. Since joining QNDX in December 2023, Tina has been instrumental in supporting the leadership team, working closely with the co-founders to ensure that the company’s strategic initiatives align with its mission to drive technological innovation while making a positive societal impact.

In her role, Tina focuses on fostering a culture of purpose-driven innovation, ensuring that QNDX’s advancements in quantum computing are utilized to create long-term benefits across sectors such as Medical, Drug Discovery, Geospatial, Science and Engineering, Aviation, Agriculture, and Cybersecurity. Her work is vital in helping QNDX navigate the complexities of the quantum industry while maintaining a strong commitment to making a meaningful difference in the world.

Before joining QNDX, Tina was deeply involved in enhancing physical security across schools, churches, municipalities, and federal buildings, with a particular focus on active shooter threat protection measures. Her efforts were instrumental in the support and education of security solutions that significantly improved safety in these critical environments.

In addition to her role at QNDX, Tina is the President of Integrated Solutions Worldwide, where she has successfully expanded federal and private sector engagements and secured high-value contracts. Her extensive experience in strategic business development, combined with her past work, makes her a vital leader at QNDX.

Tina holds an MBA from WashU, Olin School of Business, St. Louis, and an Associate of Applied Science in Physical Therapy. Her dedication to supporting QNDX’s leadership and fostering a purpose-driven approach to innovation underscores her commitment to ensuring that the company’s growth is both impactful and sustainable.

Rony Takchi is currently a consultant at QNDX where he serves as a subject matter expert on pancreatic cancer research and contributes to knowledge dissemination to identify opportunities to apply quantum computing to address challenges in pancreatic cancer treatment. This follows a successful six-year postdoctoral research fellowship at WashU, St. Louis where he made significant contributions to the field of pancreatic cancer research. 

Dr. Takchi is the lead author on a project published at Nature – Cell Death & Disease, which identified the mechanism of cancer cell death induced by sigma-2 ligands. This is one of his eight first-author publications (including articles and abstracts) and numerous presentations at national conferences. Additionally, his collaborations have resulted in seven additional publications, demonstrating his strong teamwork and communication skills. 

Rony Takchi is a medical doctor with his MD and BS in Biology from the Lebanese American University in Byblos, Lebanon. He is married to his wife Julia, and they have one baby boy, Mateo, whom they adore. Dr. Takchi loves cooking for his family and playing soccer weekly.

Connor Freeman is a Research Assistant at QNDX and a medical student at Saint Louis University School of Medicine with his bachelor’s degree in biomedical engineering from Saint Louis University. Connor is passionate about the use of AI and quantum computing to promote innovative solutions for more affordable and accessible healthcare. Connor is currently the Chair of the Service Committee within SLU’s Medical School Government while engaging in tutoring of his fellow classmates and research within Pediatric Cardiology.